ABSTRACI To assess the diagnostic value of measuring free plasma deoxyribonucleic acid (DNA) in patients suspected of having pulmonary embolism, we prospectively assayed the plasma of 40 consecutive patients who underwent pulmonary angiography for the presence of free plasma DNA. Fifteen of them had angiographic evidence of pulmonary embolism. Of these 15 only two (13%) had a positive result in the test for free double-stranded plasma DNA. We concluded that measuring free double-stranded plasma DNA is of no value in the diagnosis of pulmonary embolism.
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Pulmonary embolism is the most common preventable cause of hospital death' and the third most frequent cause of death in the United States. 2 In making the diagnosis of pulmonary embolism, the clinician requires diagnostic studies which are both sensitive and specific. Recently, Sipes and coworkers3 reported that detection of free plasma DNA was 83% sensitive and "extremely specific" for the diagnosis of pulmonary embolism. In their study the diagnostic criterion for a pulmonary embolism was a "high-probability" lung scan. Radionuclide perfusion scanning is sensitive but relatively non-specific in the diagnosis of pulmonary embolism.4 Pulmonary angiography with selective lobar and segmental injection is both highly sensitive and specific.4 The purpose of our study was to assess the value of plasma DNA in the diagnosis of pulmonary embolism, the pulmonary angiogram being used as the diagnostic standard. exclude patients with diagnoses known to be associated with raised concentrations of free plasma DNA.
Methods
Pulmonary angiograms were performed by an experienced angiographer using the Seldinger technique via a femoral vein. All except one of the studies were performed within 48 hours of the onset of symptoms. The single exception was performed within 72 hours. Standard diagnostic criteria of intravascular filling defects and vessel "cut-offs" were applied. All angiograms were read without knowledge of the results of the plasma DNA assay.
Forty plasma specimens from patients with systemic lupus erythematosus that were positive for antibody to double-stranded DNA by the Crithidia luciliae assay were screened for potential use in the counterimmunoelectrophoresis (CIE) method for the detection of free plasma DNA. A specimen producing a visible precipitin line within the 1-g DNA standard was used for testing patients' specimens. This specimen had an anti-DNA titre of 1/320.
The DNA standard (Sigma Chemical Corporation, 3500 Dekalb Street, St Louis, Missouri 63118) was dissolved to make a solution of 100 mg/dl. The positive control in each plate was 1-5 ,ug/ml.6
The plasma was separated from the patients' blood samples by centrifugation and heated for one hour at 56°C to destroy complement activity. The plasma samples were then frozen at -70°C until tested at a later date. Counter-current electrophoresis was performed on commercially prepared plates (Cordis Laboratories, Miami 
Results
The pulmonary angiograms of 15 out of 40 patients were positive for pulmonary embolism. Of these 15 patients, two (13%) had a positive result in the test for free plasma DNA. None of the 25 patients with negative angiograms had a positive result in the test for free plasma DNA. The patients with negative angiograms had various diagnoses, including congestive heart failure, pneumonia, sepsis, recent abdominal surgery, cardiomyopathy, metastatic cancer, pleural effusion of unknown aetiology, and chest wall pain.
Discussion
Our study was designed to assess the diagnostic value of measuring free plasma DNA in patients with acute pulmonary embolism confirmed by pulmonary angiography. Our data show a sensitivity of 13% in a group of 15 patients with angiographically proved pulmonary emboli. An 83% sensitivity was found in a previous study, in which a pulmonary embolism was established on the basis of a highprobability lung scan only. 3 The difference between our findings and those reported by others356 is probably due to the specificity of the criteria used to diagnose a pulmonary embolus. Lung scans are relatively non-specific by comparison with pulmonary angiography. Even when ventilation scanning is combined with perfusion scanning absolute specificity is rarely possible.7
It is also possible that these discrepancies in results are due to a difference in the antibody used to detect free plasma DNA. Because the Crithidia luciliae assay was used in screening for a test serum our antibody would detect only double-stranded DNA. It was, however, double-stranded DNA that was reported to be present in the plasma of patients with pulmonary embolism.56
The fact that our study showed no false positives is surprising in view of the multiple conditions in which free plasma DNA has been found. The sensitivities of our antiserum and the antiserum used by Sipes et al were similar. The lack of false positives in our study may simply reflect the specificity of our antiserum for double-stranded DNA, although this was not documented. Sipes et al, 3 
